|
|
R2联合奥布替尼治疗高龄初诊弥漫大B细胞淋巴瘤1例并文献复习
|
Abstract:
患者，女，85岁，该患者初诊断为非生发中心型(non-GCB型)弥漫大B细胞淋巴瘤(Diffuse Large B-Cell Lymphoma, DLBCL) IV期A组，IPI 4分高危，KPS评分：40分，PS评分：3~4分，既往有冠心病史，免疫组化：CD20 (+)，Ki-67 (约80%+)，CD79a (+)，PAX5 (+)，CD19 (+)，BCL-2 (约85%中+)，BCL-6 (约25%中–弱+)，MUM-1 (约30%中–弱+)，C-myc (约20%中–弱+)，P53 (约85%中–强+)，CD15 (+)，CD30 (+)，CyclinD1 (？)，CD34 (灶+)，采用R2 (利妥昔单抗 + 来那度胺)联合奥布替尼方案治疗后颈部肿块明显缩小，疗效较满意。本文阐述高龄弥漫大B细胞淋巴瘤患者诊断经过、治疗方案及文献回顾。
The patient, an 85-year-old female, was initially diagnosed with non-germinal center (non-GCB) diffuse large B-cell lymphoma stage IV group A, IPI score 4, high-risk, KPS score: 40 points, PS score: 3~4 points, previous history of coronary artery disease, immunohistochemistry: CD20 (+), Ki-67 (about 80%+), CD79a (+), PAX5 (+), CD19 (+), BCL-2 (about 85% medium+), BCL-6 (about 25% medium-weak+), MUM-1 (about 30% medium-weak+), C-myc (about 20% medium-weak+), P53 (about 85% medium-strong+), CD15 (+), CD30 (+), CyclinD1 (？), CD34 (foci+), R2 (rituximab + lenalidomide) combined with orelabrutinib regimen after treatment with neck lump significantly reduced, and the efficacy was satisfactory. This article describes the diagnosis, treatment regimen and literature review of elderly patients with diffuse large B-cell lymphoma.
| [1] | Li, S., Young, K.H. and Medeiros, L.J. (2018) Diffuse Large B-Cell Lymphoma. Pathology, 50, 74-87. https://doi.org/10.1016/j.pathol.2017.09.006 |
| [2] | Di, M., Huntington, S.F. and Olszewski, A.J. (2020) Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. The Oncologist, 26, 120-132. https://doi.org/10.1002/onco.13610 |
| [3] | Ansell, S.M. (2015) Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic Proceedings, 90, 1152-1163. https://doi.org/10.1016/j.mayocp.2015.04.025 |
| [4] | Hashmi, A.A., Iftikhar, S.N., Nargus, G., Ahmed, O., Asghar, I.A., Shirazi, U.A., et al. (2021) Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma. Cureus, 13, e1312. https://doi.org/10.7759/cureus.13120 |
| [5] | Susanibar‐Adaniya, S. and Barta, S.K. (2021) 2021 Update on Diffuse Large B Cell Lymphoma: A Review of Current Data and Potential Applications on Risk Stratification and Management. American Journal of Hematology, 96, 617-629. https://doi.org/10.1002/ajh.26151 |
| [6] | Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., et al. (2015) Diffuse Large B-Cell Lymphoma (DLBCL): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 26, v116-v125. https://doi.org/10.1093/annonc/mdv304 |
| [7] | Lv, L., Qi, X., Wang, C., Ma, Y., Nie, Y., Abulaiti, R., et al. (2023) Identification of FAT4 as a Positive Prognostic Biomarker in DLBCL by Comprehensive Genomic Analysis. Clinical and Experimental Medicine, 23, 2675-2685. https://doi.org/10.1007/s10238-023-01018-z |
| [8] | Xu, P., Shi, Z., Qian, Y., Cheng, S., Zhu, Y., Jiang, L., et al. (2022) Ibrutinib, Rituximab, and Lenalidomide in Unfit or Frail Patients Aged 75 Years or Older with De Novo Diffuse Large B-Cell Lymphoma: A Phase 2, Single-Arm Study. The Lancet Healthy Longevity, 3, e481-e490. https://doi.org/10.1016/s2666-7568(22)00123-4 |
| [9] | Nowakowski, G.S. and Czuczman, M.S. (2015) ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection? American Society of Clinical Oncology Educational Book, 35, e449-e457. https://doi.org/10.14694/edbook_am.2015.35.e449 |
| [10] | Zhu, Y., Zhang, X., Wei, J., Yang, C., Tong, H., Mai, W., et al. (2022) Rituximab, Lenalidomide and BTK Inhibitor as Frontline Treatment for Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma: A Real-World Analysis of Single Center. Experimental Hematology & Oncology, 11, Article No. 57. https://doi.org/10.1186/s40164-022-00314-w |
| [11] | Westin, J., Davis, R.E., Feng, L., Hagemeister, F., Steiner, R., Lee, H.J., et al. (2023) Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients with Newly Diagnosed Large B-Cell Lymphoma. Journal of Clinical Oncology, 41, 745-755. https://doi.org/10.1200/jco.22.00597 |
| [12] | Yu, H., Wang, X., Li, J., Ye, Y., Wang, D., Fang, W., et al. (2021) Addition of BTK Inhibitor Orelabrutinib to Rituximab Improved Anti-Tumor Effects in B Cell Lymphoma. Molecular Therapy—Oncolytics, 21, 158-170. https://doi.org/10.1016/j.omto.2021.03.015 |
